Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

ABSTRACT There is no clinical evidence supporting the use of polymyxin B in combination with another antimicrobial for infections caused by extensively drug-resistant Acinetobacter baumannii or Pseudomonas aeruginosa isolates. We developed a cohort study of patients in two intensive care units from teaching hospitals to evaluate treatment with intravenous polymyxin B for ≥48 h for severe A. baumannii or P. aeruginosa infections. Covariates potentially associated with 30-day mortality were evaluated in a Cox proportional hazards model. A total of 101 patients were included; 33 (32.7%) were treated with polymyxin B in combination with an antimicrobial lacking in vitro activity and 68 (67.3%) with polymyxin B in monotherapy. The overall 30-day mortality was 59.4% (60 patients), comprising 42.4% (14 of 33) and 67.6% (46 of 68) in combination and monotherapy groups, respectively (P = 0.03). The mortality rates were 18.5/1,000 patient days and 36.4/1,000 patient days in the combination and monotherapy groups, respectively (P = 0.02). Combination therapy was independently associated with lower 30-day mortality (hazard ratio, 0.33; 95% confidence interval, 0.17 to 0.64; P = 0.001). Creatinine clearance of ≥60 ml/min was also a protective factor, while a higher acute physiology and chronic health evaluation (APACHE II) score and polymicrobial infection were associated with increased mortality. The results did not change after adding a propensity score for prescribing combination therapy into the model. The protective effect remained when only combination with β-lactam or carbapenem was considered and in both subgroups of patients: those with A. baumannii infection and those with lower respiratory tract infections. To our knowledge, this is the first clinical study to show a benefit of combination over monotherapy with polymyxin B for severe extensively drug-resistant A. baumannii or P. aeruginosa infections.

[1]  Brian T. Tsuji,et al.  Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use , 2015, Pharmacotherapy.

[2]  J. Vincent,et al.  Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa* , 2014, Critical care medicine.

[3]  L. Leibovici,et al.  Combination therapy for carbapenem-resistant Gram-negative bacteria. , 2014, The Journal of antimicrobial chemotherapy.

[4]  J. Li,et al.  Colistin and polymyxin B: peas in a pod, or chalk and cheese? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Bonomo,et al.  The deadly impact of extreme drug resistance in Acinetobacter baumannii. , 2014, Critical care medicine.

[6]  V. Miriagou,et al.  Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems , 2014, Antimicrobial Agents and Chemotherapy.

[7]  C. Landersdorfer,et al.  Combination therapy for carbapenem-resistant Gram-negative bacteria , 2013, Expert review of anti-infective therapy.

[8]  G. Signoriello,et al.  Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  S. Suh,et al.  Comparison of the Vitek 2, MicroScan, and Etest Methods with the Agar Dilution Method in Assessing Colistin Susceptibility of Bloodstream Isolates of Acinetobacter Species from a Korean University Hospital , 2013, Journal of Clinical Microbiology.

[11]  M. Bassetti,et al.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  F. Kokturk,et al.  Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia , 2012, Epidemiology and Infection.

[13]  P. Bispo,et al.  Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results , 2012, Journal of Clinical Microbiology.

[14]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  L. Saiman,et al.  Comparison of Polymyxin B, Tigecycline, Cefepime, and Meropenem MICs for KPC-Producing Klebsiella pneumoniae by Broth Microdilution, Vitek 2, and Etest , 2011, Journal of Clinical Microbiology.

[16]  Clsi.  Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[17]  A. Zavascki,et al.  The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. , 2010, The Journal of antimicrobial chemotherapy.

[18]  M. Roberts,et al.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. , 2009, The Journal of antimicrobial chemotherapy.

[19]  Margaret A Dudeck,et al.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. , 2008, American journal of infection control.

[20]  Jian Li,et al.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. , 2007, The Journal of antimicrobial chemotherapy.

[21]  M. Falagas,et al.  Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.